BG
NKTR icon

BlackRock Group’s Nektar Therapeutics NKTR Stock Holding History

BlackRock Group’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$3.72M Buy
20,216
+6,999
+53% +$1.42M ﹤0.01% 1350
2016
Q3 		$3.41M Buy
13,217
+681
+5% +$175K ﹤0.01% 1294
2016
Q2 		$2.68M Buy
12,536
+856
+7% +$191K ﹤0.01% 1378
2016
Q1 		$2.41M Buy
11,680
+956
+9% +$184K ﹤0.01% 1424
2015
Q4 		$2.71M Buy
10,724
+132
+1% +$27.1K ﹤0.01% 1330
2015
Q3 		$1.74M Sell
10,592
-1,594
-13% -$282K ﹤0.01% 1583
2015
Q2 		$2.29M Buy
12,186
+7,642
+168% +$1.32M ﹤0.01% 1483
2015
Q1 		$750K Buy
4,544
+545
+14% +$112K ﹤0.01% 2023
2014
Q4 		$930K Buy
3,999
+140
+4% +$29.9K ﹤0.01% 1923
2014
Q3 		$698K Buy
3,859
+455
+13% +$87.1K ﹤0.01% 2003
2014
Q2 		$655K Sell
3,404
-4,450
-57% -$787K ﹤0.01% 2069
2014
Q1 		$1.43M Buy
7,854
+184
+2% +$36.4K ﹤0.01% 1805
2013
Q4 		$1.3M Buy
7,670
+336
+5% +$54.2K ﹤0.01% 1815
2013
Q3 		$1.15M Hold
7,334
– – ﹤0.01% 1825
2013
Q2 		$1.27M Buy
+7,334
New +$1.12M ﹤0.01% 1573

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Group's NKTR Position: Q4 2016 in Review

BlackRock Group increased its Nektar Therapeutics (NKTR) stake by 53% in Q4 2016, buying an estimated $1.42M and bringing the position to 20,216 shares worth $3.72M. The position accounts for ﹤0.01% of the portfolio, ranked #1350.

BlackRock Group first reported a position in NKTR in Q2 2013 and has held it in 15 quarters since. 199 funds tracked by Wall St. Rank hold NKTR as of Q4 2016.

  • BlackRock Group held 20,216 shares of Nektar Therapeutics worth $3.72M as of Q4 2016.
  • BlackRock Group bought 6,999 Nektar Therapeutics shares in Q4 2016, an estimated $1.42M.
  • Nektar Therapeutics made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #1350 holding.
  • BlackRock Group first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 15 quarters since.
  • 199 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.